...
首页> 外文期刊>The Korean Journal of Parasitology >In Vitro Infectivity Assessment by Drug Susceptibility Comparison of Recombinant Leishmania major Expressing Enhanced Green Fluorescent Protein or EGFP-Luciferase Fused Genes with Wild-Type Parasite
【24h】

In Vitro Infectivity Assessment by Drug Susceptibility Comparison of Recombinant Leishmania major Expressing Enhanced Green Fluorescent Protein or EGFP-Luciferase Fused Genes with Wild-Type Parasite

机译:通过药物敏感性比较重组利什曼原虫表达增强型绿色荧光蛋白或EGFP-荧光素酶融合基因与野生型寄生虫的体外药敏性评估。

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Leishmaniasis is a worldwide uncontrolled parasitic disease due to the lack of effective drug and vaccine. To speed up effective drug development, we need powerful methods to rapidly assess drug effectiveness against the intracellular form of Leishmania in high throughput assays. Reporter gene technology has proven to be an excellent tool for drug screening in vitro. The effects of reporter proteins on parasite infectivity should be identified both in vitro and in vivo. In this research, we initially compared the infectivity rate of recombinant Leishmania major expressing stably enhanced green fluorescent protein (EGFP) alone or EGFP-luciferase (EGFP-LUC) with the wild-type strain. Next, we evaluated the sensitivity of these parasites to amphotericin B (AmB) as a standard drug in 2 parasitic phases, promastigote and amastigote. This comparison was made by MTT and nitric oxide (NO) assay and by quantifying the specific signals derived from reporter genes like EGFP intensity and luciferase activity. To study the amastigote form, both B10R and THP-1 macrophage cell lines were infected in the stationary phase and were exposed to AmB at different time points. Our results clearly revealed that the 3 parasite lines had similar in vitro infectivity rates with comparable parasite-induced levels of NO following interferon-γ/lipopolysaccharide induction. Based on our results we proposed the more reporter gene, the faster and more sensitive evaluation of the drug efficiency.
机译:由于缺乏有效的药物和疫苗,利什曼病是世界范围内无法控制的寄生虫病。为了加快有效的药物开发,我们需要强大的方法来在高通量分析中快速评估针对利什曼原虫的细胞内形式的药物有效性。事实证明,记者基因技术是用于体外药物筛选的出色工具。在体外和体内都应确定报告蛋白对寄生虫感染性的影响。在这项研究中,我们最初比较了单独表达稳定增强的绿色荧光蛋白(EGFP)或重组EGFP-荧光素酶(EGFP-LUC)的重组利什曼原虫与野生型菌株的感染率。接下来,我们评估了这些寄生虫对作为标准药物的两性霉素B(AmB)在2个寄生虫阶段(前鞭毛体和鞭毛体)的敏感性。这种比较是通过MTT和一氧化氮(NO)测定法进行的,并且通过量化衍生自报告基因的特定信号(如EGFP强度和荧光素酶活性)进行的。为了研究the体形式,B10R和THP-1巨噬细胞均在固定期感染,并在不同时间点暴露于AmB。我们的结果清楚地表明,在干扰素-γ/脂多糖诱导后,这3种寄生虫系具有相似的体外感染率,且具有可比的寄生虫诱导的NO水平。根据我们的结果,我们提出了更多的报告基因,对药物效率的评估更快,更敏感。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号